A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology

Sponsor
Pfizer

Protocol Number
A5481082 POLARIS

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Type of Cancer
Breast Oncology

Sponsor
NRG Oncology

Protocol Number
NRG Oncology BR003

To Learn More Call
201-510-0910

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Type of Cancer
Breast Oncology

Site
Howell, Little Silver

Protocol Number
PUMA NER 1301

To Learn More Call
201-510-0910

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Type of Cancer
Breast Oncology